SCHEMBL661704

SCHEMBL661704

CCOC(=O)C(CC)Sc1nc2c(c(=O)n(C)c(=O)n2C)n1Cc1ccccc1Br

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 13/20 0.57
PCSK9 Q8NBP7 1/20 0.53
HSD17B10 Q99714 4/20 0.52
POLB P06746 1/20 0.52
HPGD P15428 1/20 0.52
NPSR1 Q6W5P4 3/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
TSHR P16473 5/20 0.50
HTT P42858 2/20 0.50
MAPT P10636 2/20 0.50
MAPK1 P28482 2/20 0.50
TP53 P04637 2/20 0.48
LMNA P02545 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
GAA P10253 1/20 0.47
MAOB P27338 1/20 0.46
ADORA2A P29274 1/20 0.46
USP2 O75604 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL662570 0.87 ALDH1A1 (0.62) ALDH1A1HSD17B10POLBHPGDNPSR1
SCHEMBL661222 0.85 ALDH1A1 (0.56) ALDH1A1HSD17B10POLBHPGDNPSR1
SCHEMBL30361110 0.84 ALDH1A1 (0.61) ALDH1A1HSD17B10POLBHPGDNPSR1
SCHEMBL661185 0.84 ALDH1A1 (0.61) ALDH1A1HSD17B10POLBHPGDNPSR1
SCHEMBL661150 0.83 ALDH1A1 (0.74) ALDH1A1HSD17B10POLBHPGDNPSR1
SCHEMBL8243853 0.81 ALDH1A1 (0.61) ALDH1A1PCSK9HSD17B10POLBHPGD
SCHEMBL17938016 0.81 PCSK9 (0.57) ALDH1A1PCSK9HSD17B10HPGDNPSR1
SCHEMBL8243849 0.78 ALDH1A1 (0.60) ALDH1A1PCSK9HSD17B10POLBHPGD
SCHEMBL3372363 0.77 ALDH1A1 (0.60) ALDH1A1PCSK9HSD17B10NPSR1TSHR
SCHEMBL661628 0.77 ALDH1A1 (0.52) ALDH1A1HSD17B10POLBHPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090018148-A1 Xanthine Derivatives, Processes For Preparing Them And Their Uses UCB PHARMA, S.A. (BE) 2009-01-15 US claimed
EP-1963325-A2 XANTHINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB Pharma, S.A. (BE) 2008-09-03 EP claimed
WO-2007065595-A2 XANTHINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB PHARMA, S.A. (BE) 2007-06-14 WO claimed
US-20240293363-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION UNIV JOHNS HOPKINS (US) 2024-09-05 US disclosed
US-20230277501-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2023-09-07 US disclosed
US-20230033195-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2023-02-02 US disclosed
US-20220265685-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2022-08-25 US disclosed
US-20220218665-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION UNIV JOHNS HOPKINS (US) 2022-07-14 US disclosed
US-11160785-B2 Methods and compositions for improving cognitive function AGENEBIO INC. (US) 2021-11-02 US disclosed
US-20210244709-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2021-08-12 US disclosed
EP-3827820-A1 BRIVARACETAM FOR IMPROVING COGNITIVE FUNCTION The Johns Hopkins University (US) 2021-06-02 EP disclosed
US-20120214859-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2012-08-23 US disclosed
US-20120046336-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY (US) 2012-02-23 US disclosed
US-20110212928-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY (US) 2011-09-01 US disclosed
EP-2346500-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION The Johns Hopkins University (US) 2011-07-27 EP disclosed
US-20100099735-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2010-04-22 US disclosed
WO-2010044878-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY (US) 2010-04-22 WO disclosed
US-20090018148-A1 Xanthine Derivatives, Processes For Preparing Them And Their Uses UCB PHARMA, S.A. (BE) 2009-01-15 US disclosed
EP-1963325-A2 XANTHINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB Pharma, S.A. (BE) 2008-09-03 EP disclosed
WO-2007065595-A2 XANTHINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB PHARMA, S.A. (BE) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046336-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE2, RAB2A, VAMP8 ALDH1A1 2819/4885PCSK9 276/4885HSD17B10 2745/4885
US-20210244709-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION GRIN2A, CHRNA2, SYNGR2 ALDH1A1 2177/4885PCSK9 725/4885HSD17B10 929/4885
US-20090018148-A1 Xanthine Derivatives, Processes For Preparing Them And Their Uses XDH, HPRT1, UGT1A1 ALDH1A1 243/4885PCSK9 52/4885HSD17B10 812/4885
US-11160785-B2 Methods and compositions for improving cognitive function BACE2, BACE1, GRIN2A ALDH1A1 1226/4885PCSK9 1154/4885HSD17B10 2514/4885
US-20100099735-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE2, RAB2A, VAMP8 ALDH1A1 2819/4885PCSK9 276/4885HSD17B10 2745/4885
US-20240293363-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE2, RAB2A, VAMP8 ALDH1A1 2819/4885PCSK9 276/4885HSD17B10 2745/4885
US-20120214859-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION GRIN2A, GRIN2D, SLC18A2 ALDH1A1 1780/4885PCSK9 1435/4885HSD17B10 1787/4885
US-20220218665-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE2, RAB2A, VAMP8 ALDH1A1 2819/4885PCSK9 276/4885HSD17B10 2745/4885
US-20230277501-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION GRIN2A, CHRNA2, SYNGR2 ALDH1A1 2177/4885PCSK9 725/4885HSD17B10 929/4885
US-20220265685-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE1, BACE2, ACHE ALDH1A1 2614/4885PCSK9 1076/4885HSD17B10 1998/4885
US-20110212928-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE1, BACE2, ACHE ALDH1A1 2614/4885PCSK9 1076/4885HSD17B10 1998/4885
US-20230033195-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION GRIN2D, GRIN2A, SLC18A2 ALDH1A1 2755/4885PCSK9 1145/4885HSD17B10 1789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.